Featured News

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001 trial is testing larazotide acetate—also known as INN-202—as an adjunct treatment for patients with celiac disease still experiencing symptoms on a gluten-free diet. Larazotide acetate…

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

I’m writing to invite you to join me and others from across the healthcare community at the 2019 Patient-Centered Outcomes Research Institute (PCORI) Annual Meeting, being held September 18-20 at the Marriott Wardman Park Hotel in Washington, DC. As a member of PCORI’s Advisory Panel on Patient Engagement, I know firsthand that PCORI’s staff is…

Written by Francisco Leon, MD, PhD, Chief Scientific Officer, Co-Founder, Provention Bio Current guidelines recommend routine follow-up for celiac disease with dietary interviews and celiac blood tests, though these methods are not accurate measures of gluten-free diet (GFD) adherence. A recent study in Spain tested the use of gluten immunogenic peptides (GIP)—a direct measure of…

Researchers at the Mayo Clinic recently found that nutrient deficiencies are often the only sign of celiac disease in undiagnosed adults. It is suspected that as many as 50 percent of adults with celiac disease are undiagnosed due to atypical symptoms. There are many potential signs of celiac disease, but doctors often only look for…

ImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.

At the Digestive Disease Week meeting in San Diego, researchers from Takeda and the Celiac Disease Foundation presented a study entitled, Adherence to the gluten-free diet and celiac patients outcomes: real world evidences from an international patient registry, iCureCeliac®. 

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!

There is significant overlap between NCGS and IBS. Gluten may not be the only culprit; other wheat compounds also play roles that might be the key to the difference in how NCGS and IBS are affected by eating wheat.

The Celiac Disease Foundation was proud to be a sponsor of the MedAboutData Hackathon in Haifa, Israel. During the hackathon, the ‘CeliACT’ team presented an innovative product that can assist in early detection of celiac disease.